Advances in systemic therapies for metastatic castration-resistant prostate cancer

Future Oncology

Volumn 10, Issue 14, 2014, Pages 2213-2226

  Pant, Manish K ^a   Abughaban, Ahmed ^a   Aragon Ching, Jeanny B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

abiraterone acetate; androgen deprivation therapy; chemotherapy; enzalutamide; immunotherapy; metastatic castration resistant prostate cancer; radium; zoledronic acid

Indexed keywords

4 [7 [6 CYANO 5 (TRIFLUOROMETHYL) 3 PYRIDINYL] 8 OXO 6 THIOXO 5,7 DIAZASPIRO[3.4]OCTAN 5 YL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CABOZANTINIB; DEGARELIX; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; PLACEBO; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RADIUM; RADIUM CHLORIDE RA 223; SIPULEUCEL T; SUNITINIB; ZOLEDRONIC ACID;

ANDROGEN SYNTHESIS; ANTIANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; SYSTEMIC THERAPY; TUMOR IMMUNITY; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84916628845     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.128     Document Type: Review

References (69)

1. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N. Eng. J. Med. 311(20), 1281-1286 (1984).
2. Crawford ED, Tombal B, Miller K et al. A Phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 186(3), 889-897 (2011).
3. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Eng. J. Med. 364(21), 1995-2005 (2011).
4. Ryan CJ, Smith MR, De Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Eng. J. Med. 368(2), 138-148 (2013).
5. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Eng. J. Med. 367(13), 1187-1197 (2012).
6. Medivation and Astellas Announce the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer (2013). http://investors.medivation.com
7. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756-1764 (1996).
8. Tannock IF, De Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Eng. J. Med. 351(15), 1502-1512 (2004).
9. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
10. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Eng. J. Med. 363(5), 411-422 (2010).
11. Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010).
12. Saad F, Gleason DM, Murray R et al. Long-term effcacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96(11), 879-882 (2004).
13. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768), 813-822 (2011).
14. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Eng. J. Med. 369(3), 213-223 (2013).
15. Rathkopf DE, Morris MJ, Fox JJ et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 31(28), 3525-3530 (2013).
16. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 31(4), 412-419 (2013).
17. Crawford ED, Eisenberger MA, Mcleod DG et al. A controlled trial of leuprolide with and without futamide in prostatic carcinoma. N. Eng. J. Med. 321(7), 419-424 (1989).
18. Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without futamide for metastatic prostate cancer. N. Eng. J. Med. 339(15), 1036-1042 (1998).
19. Roth BJ. New therapeutic agents for hormone-refractory prostate cancer. Semin. Oncol. 23(6 Suppl. 14), 49-55 (1996).
20. Hussain M, Tangen CM, Berry DL et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Eng. J. Med. 368(14), 1314-1325 (2013).
21. Mohler JL, Kantoff PW, Armstrong AJ et al. Prostate cancer, version 1.2014. J. Natl Compr. Canc. Netw. 11(12), 1471-1479 (2013).
22. Kelly WK, Gomella LG. Androgen deprivation therapy and competing risks. JAMA 306(21), 2382-2383 (2011).
23. Klotz L, Boccon-Gibod L, Shore ND et al. The effcacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group Phase III study in patients with prostate cancer. BJU Int. 102(11), 1531-1538 (2008).
24. Damber JE, Tammela TL, Iversen P et al. The effect of baseline testosterone on the effcacy of degarelix and leuprolide: further insights from a 12-month, comparative, Phase III study in prostate cancer patients. Urology 80(1), 174-180 (2012).
25. Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev. Urol. 11(2), 52-60 (2009).
26. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplifcation of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9(4), 401-406 (1995).
27. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Eng. J. Med. 332(21), 1393-1398 (1995).
28. Gioeli D, Ficarro SB, Kwiek JJ et al. Androgen receptor phosphorylation. Regulation and identifcation of the phosphorylation sites. J. Biol. Chem. 277(32), 29304-29314 (2002).
29. Kinoshita H, Shi Y, Sandefur C et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60(13), 3623-3630 (2000).
30. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10(1), 33-39 (2004).
31. Holzbeierlein J, Lal P, Latulippe E et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifes androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 164(1), 217-227 (2004).
32. Sartor AO, Tangen CM, Hussain MH et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112(11), 2393-2400 (2008).
33. Hara T, Miyazaki J, Araki H et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63(1), 149-153 (2003).
34. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375 (9724), 1437-1446 (2010).
35. Beer TM, Armstrong AJ, Sternberg CN et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): Results of Phase III PREVAIL study. J. Clin. Oncol. 32(Suppl. 4), (2014). LBA1
36. Berthold DR, Pond GR, Soban F, De Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242-245 (2008).
37. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Eng. J. Med. 351(15), 1513-1520 (2004).
38. Lee P, Aragon-Ching JB. Cytotoxic compounds in the treatment of castration-resistant prostate cancer. Anticancer Agents Med. Chem. 9(10), 1040-1045 (2009).
39. JEVTANA (cabazitaxel) injection Label-Accessdata FDA. www.accessdata.fda.gov
40. Copier J, Dalgleish A. Whole-cell vaccines: a failure or a success waiting to happen? Curr. Opin. Mol. Ther. 12(1), 14-20 (2010).
41. Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev. Vaccines 10(6), 743-753 (2011).
42. Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specifc antigen is associated with a greater overall survival beneft from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 81(6), 1297-1302 (2013).
43. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006).
44. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009).
45. Mehra R, Kumar-Sinha C, Shankar S et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin. Cancer Res. 17(12), 3924-3932 (2011).
46. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin. Oncol. 21(5), 630-656 (1994).
47. El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: evolving Paradigms. Prostate Cancer 2013, (2013). 210686
48. Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis. 5(4), 264-272 (2002).
49. Aragon-Ching JB. Unravelling the role of denosumab in prostate cancer. Lancet 377(9768), 785-786 (2011).
50. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Signifcant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 62(11), 3120-3125 (2002).
51. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J. Nucl. Med. 44(2), 252-259 (2003).
52. Cookson MS, Roth BJ, Dahm P et al. Castration-resistant prostate cancer: AUA Guideline. J. Urol. 190(2), 429-438 (2013).
53. Heidenreich A, Bastian PJ, Bellmunt J et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur. Urol. 65(2), 467-479 (2013).
54. Mezynski J, Pezaro C, Bianchini D et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 23(11), 2943-2947 (2012).
55. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann. Oncol. 24 (7), 1802-1807 (2013).
56. Pezaro CJ, Omlin AG, Altavilla A et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur. Urol. 66(3), 459-465 (2014).
57. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73(2), 483-489 (2013).
58. Carver BS, Chapinski C, Wongvipat J et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-defcient prostate cancer. Cancer Cell 19 (5), 575-586 (2011).
59. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72(6), 1494-1503 (2012).
60. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).
61. Kelly WK, Halabi S, Carducci M et al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30 (13), 1534-1540 (2012).
62. Michaelson MD, Oudard S, Ou YC et al. Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer. J. Clin. Oncol. 32(2), 76-82 (2014).
63. Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 (COMET-1). https://clinicaltrials.gov
64. Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2). https://clinicaltrials.gov
65. Mckay RR, Choueiri TK, Taplin ME. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs 73(13), 1417-1430 (2013).
66. Mostaghel EA, Nelson PS, Lange P et al. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J. Clin. Oncol. (2013).
67. Van Soest RJ, Van Royen ME, De Morree ES et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur. J. Cancer 49 (18), 3821-3830 (2013).
68. Crawford ED, Stone NN, Yu EY et al. Challenges and Recommendations for Early Identifcation of Metastatic Disease in Prostate Cancer. Urology, 83(3), 664-669 (2014).
69. Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP. The utility of prostate-specifc antigen in the management of advanced prostate cancer. BJU Int. 112 (5), 548-560 (2013).